Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 11, Issue 7, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-09
DOI
10.1038/s41408-021-00518-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
- (2021) Peter Borchmann et al. LANCET ONCOLOGY
- Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
- (2021) Reid W. Merryman et al. LEUKEMIA
- Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial
- (2020) Sarah Gillessen et al. BLOOD
- Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort
- (2020) Reid W Merryman et al. BLOOD
- PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma
- (2020) Alex F. Herrera et al. BLOOD
- Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
- (2020) Alison J. Moskowitz et al. BLOOD
- Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years
- (2020) Christopher A. Yasenchak et al. BLOOD
- Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study
- (2020) Aspasia Stamatoullas et al. BLOOD
- Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study
- (2020) David J. Straus et al. BLOOD
- Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma
- (2020) Jeries Kort et al. LEUKEMIA & LYMPHOMA
- Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression
- (2020) Talha Badar et al. BRITISH JOURNAL OF HAEMATOLOGY
- KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
- (2020) John Kuruvilla et al. JOURNAL OF CLINICAL ONCOLOGY
- Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy
- (2020) Juan C. Nieto et al. LEUKEMIA
- Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
- (2020) Paul J. Bröckelmann et al. JAMA Oncology
- A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
- (2020) Nancy L. Bartlett et al. BLOOD
- Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
- (2020) Carlos A. Ramos et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma
- (2020) Pamela Blair Allen et al. BLOOD
- Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
- (2020) Catherine S Diefenbach et al. Lancet Haematology
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
- (2019) Philippe Armand et al. BLOOD
- Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
- (2019) Guillaume Manson et al. EUROPEAN JOURNAL OF CANCER
- ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT-301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL)
- (2019) G. Collins et al. HEMATOLOGICAL ONCOLOGY
- Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP‐EBMT study
- (2019) Ali Bazarbachi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)
- (2019) Herve Ghesquieres et al. BLOOD
- Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting
- (2018) Auayporn Nademanee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
- (2018) Anne-Ségolène Cottereau et al. BLOOD
- Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
- (2018) Ann S. LaCasce et al. BLOOD
- Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin’s lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy
- (2018) Jordan Gauthier et al. BONE MARROW TRANSPLANTATION
- Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party
- (2018) Ali Bazarbachi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors Before and After Allogeneic transplantation
- (2018) Awais Ijaz et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
- (2018) Craig H. Moskowitz et al. BLOOD
- Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.
- (2018) Olivier Casasnovas et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party
- (2018) Ali Bazarbachi et al. CANCER
- Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials
- (2017) Stephanie Sasse et al. JOURNAL OF CLINICAL ONCOLOGY
- PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
- (2017) Peter Borchmann et al. LANCET
- FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
- (2017) Yvette L. Kasamon et al. ONCOLOGIST
- Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma
- (2016) Scott D. Ramsey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30 + Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program
- (2016) Aurore Perrot et al. HAEMATOLOGICA
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
- (2016) Peter Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30 + Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program
- (2016) Aurore Perrot et al. HAEMATOLOGICA
- Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
- (2015) John Radford et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bendamustine Combined with Donor Lymphocytes Infusion in Hodgkin's Lymphoma Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
- (2014) Elisa Sala et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma
- (2014) Salim Kanoun et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions
- (2013) B. Klimm et al. ANNALS OF ONCOLOGY
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients
- (2013) Hervé Ghesquières et al. LEUKEMIA & LYMPHOMA
- Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma
- (2012) Gaetano Corazzelli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
- (2012) Bastian von Tresckow et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
- (2012) Alison J. Moskowitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Early-Stage Hodgkin's Lymphoma
- (2010) James O. Armitage NEW ENGLAND JOURNAL OF MEDICINE
- Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial
- (2009) Natacha Heutte et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now